Barclays
RNTX icon

Barclays’s Rein Therapeutics RNTX Stock Holding History

Barclays’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-2,570
Closed -$2.67K – 5817
2026
Q2 		$2.67K Buy
+2,570
New +$3.11K ﹤0.01% 4842
2021
Q4 		– Sell
-1,264
Closed -$26K – 4818
2021
Q3 		$26K Buy
1,264
+887
+235% +$19.4K ﹤0.01% 4325
2021
Q2 		$9K Sell
377
-205
-35% -$5.12K ﹤0.01% 4682
2021
Q1 		$17K Buy
+582
New +$19.9K ﹤0.01% 4396
2019
Q4 		– Sell
-4
Closed – – 6887
2019
Q3 		$0 Buy
+4
New +$55 ﹤0.01% 7203
2018
Q2 		– Sell
-57
Closed -$9K – 7351
2018
Q1 		$9K Buy
57
+27
+90% +$4.81K ﹤0.01% 6695
2017
Q4 		$6K Buy
30
+24
+400% +$5.75K ﹤0.01% 6646
2017
Q3 		$2K Buy
+6
New +$1.5K ﹤0.01% 6698

Other funds holding RNTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
University of Texas/Texas AM Investment Management Co (UTIMCO)
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $798M AUM 22.92% 1-Year Est. Return
Sigma Planning Corp
Sigma Planning Corp Ann Arbor, Michigan $3.88B AUM 23.38% 1-Year Est. Return
Gagnon Securities
Gagnon Securities New York $577M AUM 61.61% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $755M AUM 21.42% 1-Year Est. Return
Rossby Financial
Rossby Financial Melbourne, Florida $673M AUM 21.47% 1-Year Est. Return
Savant Capital
Savant Capital Rockford, Illinois $35B AUM 15.18% 1-Year Est. Return
Americana Partners
Americana Partners Houston, Texas $4.67B AUM 26.97% 1-Year Est. Return
SteelPeak Wealth
SteelPeak Wealth Woodland Hills, California $4.07B AUM 38.25% 1-Year Est. Return
Prime Capital Investment Advisors
Prime Capital Investment Advisors Overland Park, Kansas $10.2B AUM 17.74% 1-Year Est. Return

Barclays's RNTX Position: Q3 2026 in Review

Barclays sold out of Rein Therapeutics (RNTX) in Q3 2026, closing a stake of 2,570 shares — an estimated $2.67K sold.

Barclays first reported a position in RNTX in Q3 2017 and held it in 8 quarters. The position peaked at $26K in Q3 2021. 22 funds tracked by Wall St. Rank hold RNTX as of Q3 2026.

  • Barclays reported no remaining Rein Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Barclays sold 2,570 Rein Therapeutics shares in Q3 2026, an estimated $2.67K.
  • Barclays first reported a position in Rein Therapeutics in Q3 2017 and held it in 8 quarters.
  • Barclays's Rein Therapeutics position peaked at $26K in Q3 2021.
  • 22 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.